LUMO - Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today? | Benzinga
Lumos Pharma Inc (NASDAQ: LUMO) announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic (PK/PD) trial met all primary and secondary endpoints.
In March, BridgeBio Pharma Inc (NASDAQ: BBIO) said that at the highest dose level evaluated (Cohort 5, 0.25 mg/kg once daily), the mean increase from baseline in annualized height velocity for the ten children with six-month visits was ...